Secondary biomarker analysis of a phase 2 trial in 112 patients with lupus nephritis on standard therapy: anifrolumab reduced urinary CD163 and MCP-1 at week 12 vs placebo, including in proteinuric non-responders; by week 48 levels fell in all groups.
RCTn = 112
Fava et al. Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial